FIELD: pharmacology.
SUBSTANCE: claimed invention relates to field of biotechnology and immunology. Described is physiologically active protein conjugate. Protein conjugate includes physiologically active polypeptide, which is covalently connected with Fc fragment of immunoglobulin by means of polyethylene glycol. Described is method of obtaining protein conjugate. It can find application in production of various polypeptide medications of prolonged action.
EFFECT: increased physiological activity in vivo construction in comparison with native physiologically active polypeptide and increase of half-life in serum of physically active polypeptide with minimal risk of inducing undesirable immune response.
17 cl, 18 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING Fc-REGION OF IMMUNOGLOBULIN AS CARRIER | 2004 |
|
RU2352583C2 |
| LIQUID COMPOSITION OF LONG-ACTING ALPHA INTERFERON CONJUGATE | 2011 |
|
RU2613905C2 |
| POLYPEPTIDE COMPLEX CONTAINING NON-PEPTIDYL POLYMER, HAVING THREE FUNCTIONAL ENDS | 2009 |
|
RU2483081C2 |
| METHOD OF MASS PRODUCTION OF Fc REGION OF IMMUNOGLOBULIN WITH REMOTE INITIAL METHIONINE RESIDUES | 2006 |
|
RU2428430C2 |
| IMPROVED METHOD FOR PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE PRODUCTION | 2013 |
|
RU2639256C2 |
| METHOD FOR PRODUCING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX | 2012 |
|
RU2624129C2 |
| PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE SHOWING PROLONGED HALF-TIME INDEX IN VIVO | 2004 |
|
RU2312868C2 |
| INSULINOTROPIC COMPLEX IN WHICH IMMUNOGLOBULIN FRAGMENT IS USED | 2008 |
|
RU2436589C2 |
| METHOD OF CONTROLLING CONDITIONS FOR SITE-SPECIFIC BINDING OF POLYPEPTIDE AND NON-PEPTIDE POLYMER | 2010 |
|
RU2495881C2 |
| PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING INTERFERON-ALPHA CONJUGATE | 2012 |
|
RU2622077C2 |
